AzTrials
AzTrials

Cardiorespiratory ArrestCA-EEGNCT02886039

Predictive Electrophysiological Score of the Neurological Prognosis Post Cardiac Arrest

A study testing Electroencephalogram in people with Cardiorespiratory Arrest, run by University Hospital, Montpellier at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Cardiac arrest (CA) is a major public health problem (1) because of its frequency (30000 to 50000 new cases of CA per year in France), a high mortality 80-90% and a relevant morbidity : 50% of survivors have cerebral sequela. Neurologic prognostication after CA is paramount. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Cardiorespiratory Arrest
What is being tested?
Electroencephalogram
Could I receive a placebo?
No, everyone receives an active treatment
How many people
400 participants
Where
1 siteFrance
Study dates
Jun 2014to Dec 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient > 18 years, hospitalized in resuscitation
  • Cardiac arrest in hospital or out
  • Collection of the written and informed consent

Who cannot join

  • Cardiorespiratory arrest concomitant with a neurological, traumatic or toxic pathology
  • History of cerebrovascular accident or cerebral anoxia
  • Patient whose family did not give an informed consent
  • Patient < 18 years

Trial locations and contacts

1 site in 1 country.

Jean Paul ROUSTAN, MD, PhD contact

04 67 33 82 56

JP-ROUSTAN@CHU-MONTPELLIER.FR

France1 site, 1 recruiting
  • Hôpital Lapeyronie - Département Anesthésie Réanimation A

    Montpellier, 34295

    Jean-Paul ROUSTAN, MH, PhD, 04 67 33 82 56, JP-ROUSTAN@CHU-MONTPELLIER.FR

    Recruiting

Other trials in France

About this study

Cardiac arrest (CA) is a major public health problem (1) because of its frequency (30000 to 50000 new cases of CA per year in France), a high mortality 80-90% and a relevant morbidity : 50% of survivors have cerebral sequela. Neurologic prognostication after CA is paramount. The American Academy of Neurology identifies accurate predictors of poor neurologic outcome (2): clinical examination findings such as no pupil response, no corneal reflexes, no motor response to stimulation and early myoclonus status epilepticus; biologic parameters like high neuron specific enolase (NSE) greater than 33 μg/L (3-4) and electrophysiologic results like flat electroencephalogram (EEG) or with burst suppression and Somatosensory evoked potentials (SEP) with no response to N20. Brain imaging may provide additional informations but not recommended yet. However, these pronotic markers were developed before the introduction therapeutic hypothermia (TH) (5-6). TH is now recommended after cardiac arrest by international guidelines, based on demonstration of improved survival and neurological recovery in comatose survivors of CA (7). TH and its associated use of sedative and paralytic agent may delay neurologic recovery and affect the optimal timing of prognostic variables (8).

Many classifications of electroencephalogram (EEG) (9-12) exist but no one is generally accept and recommended and they were created before TH.

Read more

In a preliminary study based on a retrospective cohort of 64 patients in CA with initial TH, we developped an electroencephalographic score to predict precocity the neurologic outcome according to the Cerebral performance category (CPC) (13-14).

The purpose of this study is to evaluate a simple and objective electroencephalographic score helpful to predict neurologic outcome after CA. Then, we would like to create a composite score to have a multimodal prognostication.

Patients and methods After CA resuscitation, all patients underwent coronary angioplasty if indicated and then were immediately admitted in emergency room of ICU. All patients were intubated and mechanically ventilated. Sedation was performed with continuous infusion of midazolam 0,15-0,2 mg/kg/h and sufentanil 0,15-0,2 μg/kg/h. All our patients were curarized with cisatracurium 0,2-0,3 mg/kg/h to prevent shivering during TH and took anti-epileptic medication phenobarbital 10-15 mg/ kg two times a day to prevent infra-clinic convulsive seizure.

Mild TH between 33 -34 °C was performed by active cooling with intravascular device (CoolGard® - Zoll, Chelmsford, UK) for 24 hours. Mean arterial pressure was maintained between [75-80] mmHg by titrated norepinephrine with or without inotropics (dobutamine, epinephrine) according cardiac output monitored by echocardiography.

After 24 hours of hypothermia, warming was started at a rate of 0.2 ° C/hr; neuromuscular blocking agents were arrested at 35.5°C and sedation at 36.5°C.

Neurological evaluation performed at 48 hours off sedation included a clinical evaluation (Glasgow score, myoclonus status, response to orders, motor response to stimulation, brain-stem reflexes). NSE was sampled between 48 and 72 H. EEGs were performed at Day-2, Day-3 and Day-5 off sedation and SEP at Day-5 off sedation. All EEGs were interpreted by two certified electroencephalographers blind from clinical neurologic outcome.

Survival and neurologic outcome according to CPC were assessed at ICU discharge and three months later.

Read the detailed description

Electroencephalographic score

Reactivity Absence 1 Presence 0 Dominant frequency α (8-12 Hz) 0 θ (4-7,5 Hz) 1 δ (< 4 Hz) 2 Amplitude > 10 μV 0 < 10 μV 1 GPDs Absence 0 Presence 1 Burst Suppression Absence 0 Presence 1 Paroxysmal activity Absence 0 Presence 1

TOTAL

Being tested
Electroencephalogram
Keywords
Cardiorespiratory arrest, Neurologic outcome, Electroencephalogram, Somatosensory evoked potential, Synek classification, Cerebral performance category, Hypothermia
Medical subject headings
Heart Arrest, Hypothermia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ElectroencephalogramOther

    Prognostic evaluation of electroencephalogram score created with a retrospective cohort Creation of composite score to predict neurologic outcome in cardiorespiratory arrest

Study groups in NCT02886039
Study groupRoleWhat they receive
patientsOtherPatient with cardiac arrest benefiting an electroencephalogram
Receives: Other: Electroencephalogram

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. comparison of electroencephalogram score to neurologic outcome evaluated by cerebral performance category

    Intensive care unit discharge

    Measured: J0 (date of inclusion)

Secondary outcomes (1)
  1. comparison of electroencephalogram score to neurologic outcome evaluated by cerebral performance category

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Sep 2016 (estimated)
  2. Study startJun 2014
  3. Primary completionOct 2019 (estimated)
  4. Study completionDec 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02886039
Sponsor's protocol ID
UF 9389
Acronym
CA-EEG
Status last verified
Jul 2016
First submitted
26 Jul 2016
Last updated
1 Sep 2016
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Electroencephalogram in people with Cardiorespiratory Arrest, run by University Hospital, Montpellier at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 1 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Jean Paul ROUSTAN, MD, PhD (04 67 33 82 56, JP-ROUSTAN@CHU-MONTPELLIER.FR), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

comparison of electroencephalogram score to neurologic outcome evaluated by cerebral performance category (time frame: J0 (date of inclusion)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2016; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in